


CANCER SCIENCE INSTITUTE OF SINGAPORE IN THE SPOTLIGHT

ISSUE 54 | JUL 2018

Targeting Cancer Addiction for SALL4 with a Pharmacologic Peptide (*PNAS*, Jul 2018)

Prof Daniel Tenen's group developed a peptide drug called FFW that could effectively disrupt the activity of SALL4 – a protein related to tumour growth – in HCC, or primary liver cancer. The results of this research have implications for the treatment of HCC.



IN THIS ISSUE

Targeting Cancer Addiction for SALL4 with a Pharmacologic Peptide

Genotype-guided vs Traditional Clinical Dosing of Warfarin

Biomarkers for Homologous Recombination Deficiency in Cancer

Genotype-guided Versus Traditional Clinical Dosing of Warfarin in Patients of Asian Ancestry: a Randomized Controlled Trial. (*BMC Med*, Jul 2018)

This clinical study led by Prof Goh Boon Cher found a pharmacogenetic algorithm that could be applicable to personalize warfarin dosages in Asian patients.



Biomarkers for Homologous Recombination Deficiency in Cancer (*J Natl Cancer Inst*, May 2018)

Michal Hoppe, PhD student from Dr Anand Jeyasekharan's group published a review that summarizes the biology and clinical validation of current methods to measure HRD, to aid decision-making for patient stratification and translational research in PARP inhibitor trials.



UPCOMING EVENTS

CSI Research Meeting
17 Aug 2018

CSI Research Meeting
7 Sep 2018

4th RNA Biology Symposium
13-14 Sep 2018

AWARDS & ACHIEVEMENTS

CSI Research Fellow Wins Best Poster Award at FASEB Conference!

CSI Singapore congratulates Dr Ng Li Mei, Research Fellow from Prof Teh Bin Tean's group! Li Mei clinched the Best Poster Award after presenting her research work at the Federation of American Societies for Experimental Biology (FASEB) 4th International Conference on Retinoids. This conference was held from 10-15 June 2018 in Colorado, USA.

CSI Research Scientist Receives Travel Award at International Society for Stem Cell Research Annual Meeting 2018

Dr Junichi Matsuo, Research Scientist from Prof Yoshiaki Ito's group, submitted an abstract and was selected as a winner of a travel award for the Annual Meeting of the International Society for Stem Cell Research (ISSCR). The travel award allowed Dr Matsuo to attend the conference, which was held from 20-23 June in Melbourne, Australia, and present his excellent research work.



Frontiers in Cancer Science 2018

Registrations and abstract submissions for FCS2018 are open! Join us for an exciting time of groundbreaking scientific discovery in cancer research. Abstract submissions close on 31 August 2018.